Lantern Pharma Inc. Net Income (Loss) Available to Common Stockholders, Basic
Lantern Pharma Inc. (LTRN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$4.12 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-05-03
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$4.12M.
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$3.54M.
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$4.05M.
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$2.32M.
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$12.36M.
- Lantern Pharma Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$5.91M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$4.12M 10-Q · filed 2022-05-03 | -$7.66M derived: sum of 2 quarters · filed 2022-05-03 | -$11.72M derived: sum of 3 quarters · filed 2022-05-03 | -$14.03M derived: sum of 4 quarters · filed 2022-05-03 | |
| 2021-12-31 | -$3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$7.59M derived: sum of 2 quarters · filed 2022-03-10 | -$9.91M derived: sum of 3 quarters · filed 2022-03-10 | -$12.36M 10-K · filed 2022-03-10 | |
| 2021-09-30 | -$4.05M 10-Q · filed 2021-11-01 | -$6.37M derived: sum of 2 quarters · filed 2021-11-01 | -$8.82M 10-Q · filed 2021-11-01 | -$11.72M derived: sum of 4 quarters · filed 2022-05-03 | |
| 2021-06-30 | -$2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$4.77M 10-Q · filed 2021-07-29 | -$7.66M derived: sum of 3 quarters · filed 2022-05-03 | -$9.37M derived: sum of 4 quarters · filed 2022-05-03 | |
| 2021-03-31 | -$2.45M 10-Q · filed 2022-05-03 | -$2.32M 10-Q · filed 2021-07-29 | -$5.35M derived: sum of 2 quarters · filed 2022-05-03 | -$7.05M derived: sum of 3 quarters · filed 2022-05-03 | -$7.53M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.60M derived: sum of 2 quarters · filed 2022-03-10 | -$5.07M derived: sum of 3 quarters · filed 2022-03-10 | -$5.91M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$1.70M 10-Q · filed 2021-11-01 | -$2.18M derived: sum of 2 quarters · filed 2021-11-01 | -$3.01M 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | -$477.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$1.31M 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | -$833.42K 10-Q · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |